Biomea Fusion BMEA 深 滬
等待開盤 09-23 09:30:00 美东时间
1.70
-0.010
-0.58%
華盛通- 最 高1.78
- 今 開1.71
- 成交量 232.04万股
- 最 低 1.66
- 昨 收 1.71
- 總市值 1.23亿
- 52周最高 2.99
- 市盈率 靜 --
- 換手率 3.20%
- 52周最低 0.8719
- 委 比 -64.85%
- 總股本 7248.39万
- 歷史最高 43.69
- 量 比 1.50
- 振 幅 7.02%
- 歷史最低 0.8719
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biomea Fusion announces proposed public offering of shares
Biomea Fusion (BMEA) announced on Tuesday it had proposed an underwritten offering of common stock and pre-funded warrants, with all securities to be sold by the company. The offering includes pre-fun...
今天 04:18
Biomea Fusion Says Topline Data From Phase 1 Obesity Trial Of BMF-650 Now Expected In October, Pushed From Q3
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001840439/000119312526397870/bmea-20260922.htm
今天 04:05
Biomea Fusion to Participate in Upcoming Investor Conferences
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company focused on diabetes and obesity, announced its participation in two upcoming investor conferences: Citi's 2026 Biopharma Back to School Conference on September 10, 2026, in New York, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, also in New York. The company will present and offer one-on-one investor meetings. An audio webcast of the presenta...
09-03 12:00
美股牛股 | AI基建股SUPX狂飙24%！ALVO获美银力挺飙近19%；加密货币概念股CYPH、ZCSH双双暴升逾18%
AI基建股SUPX狂飙24%；业绩指引超预期！ALVO获美银力挺飙近19%；加密货币概念股CYPH、ZCSH双双升逾18%>>
08-25 17:38
Biomea Fusion shares are trading higher after the company announced the completion of enrollment in COVALENT-211 Phase II clinical trial evaluating icovamenib in insulin-deficient Type 2 diabetes.
Biomea Fusion shares are trading higher after the company announced the completion of enrollment in COVALENT-211 Phase II clinical trial evaluating icovamenib in insulin-deficient Type 2 diabetes.
08-24 23:02
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
Biomea Fusion announced the completion of enrollment in COVALENT-211, a Phase II trial evaluating icovamenib in insulin-deficient T2D patients. Topline 26-week data from COVALENT-211 is expected in Q1 2027, while COVALENT-212, targeting T2D patients not responding to GLP-1 therapy, continues enrollment with results anticipated in Q2 2027. Both trials aim to assess icovamenib's potential to restore beta-cell function and provide durable glycemic c...
08-24 11:00
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
Biomea Fusion has initiated a new arm of the OPAL study to evaluate the combination of icovamenib and low-dose semaglutide in overweight or obese individuals without type 2 diabetes. The randomized, double-blind study aims to assess the impact on weight loss, physical function, body composition, muscle health, and metabolic outcomes. The primary endpoint will be evaluated at Week 24. Preclinical data suggests icovamenib enhances semaglutide's eff...
08-13 11:00
Biomea Fusion Q2 EPS $(0.12) Beats $(0.22) Estimate
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 76.47 percent increase over losses of $(0.51) per share from the same period last year.
08-06 06:11
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
Biomea Fusion reported Q2 2026 financial results and business updates, including ongoing Phase II clinical trials for icovamenib in T2D patients and collaboration with Leicester University for obesity research. The company also expanded its BMF-650 obesity trial and expects initial weight loss data by Q3 2026. Cash runway extends into Q2 2027.
08-05 20:05
